SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107081545v1
22/5/498    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by de Sola LLopis, S.
Right arrow Articles by de la Torre, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Sola LLopis, S.
Right arrow Articles by de la Torre, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study

S. de Sola LLopis

Behavioral Neurology and Dementia Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

M. Miguelez-Pan

Behavioral Neurology and Dementia Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

J. Peña-Casanova

Behavioral Neurology and Dementia Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

S. Poudevida

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

M. Farré

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, and Universitat Autònoma de Barcelona (UDIMAS), Barcelona, Spain

R. Pacifici

Drug Control and Evaluation Department, Istituto Superiore di Sanità, Rome, Italy

P. Böhm

Behavioral Neurology and Dementia Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

S. Abanades

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, and Universitat Autònoma de Barcelona (UDIMAS), Barcelona, Spain

A. Verdejo García

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, Barcelona, Spain

K. Langohr

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, and Universitat Politécnica de Catalunya (UPC), Barcelona, Spain

P. Zuccaro

Drug Control and Evaluation Department, Istituto Superiore di Sanità, Rome, Italy

R. de la Torre

Human Pharmacology and Clinical Neurosciences Research Group, Neuropsychopharmacology Program, IMIM-Hospital del Mar, and Universitat Pompeu Fabra (CEXS-UPF), Barcelona, Spain, rtorre{at}imim.es

There is important preclinical evidence of long lasting neurotoxic and selective effects of ecstasy MDMA on serotonin systems in non-human primates. In humans long-term recreational use of ecstasy has been mainly associated with learning and memory impairments. The aim of the present study was to investigate the neuropsychological profile associated with ecstasy use within recreational polydrug users, and describe the cognitive changes related to maintained or variable ecstasy use along a two years period. We administered cognitive measures of attention, executive functions, memory and learning to three groups of participants: 37 current polydrug users with regular consumption of ecstasy and cannabis, 23 current cannabis users and 34 non-users free of illicit drugs. Four cognitive assessments were conducted during two years. At baseline, ecstasy polydrug users showed significantly poorer performance than cannabis users and non-drug using controls in a measure of semantic word fluency. When ecstasy users were classified according to lifetime use of ecstasy, the more severe users (more than 100 tablets) showed additional deficits on episodic memory. After two years ecstasy users showed persistent deficits on verbal fluency, working memory and processing speed. These findings should be interpreted with caution, since the possibility of premorbid group differences cannot be entirely excluded. Our findings support that ecstasy use, or ecstasy/cannabis synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for long-term cognitive impairment owing to ecstasy consumption in the context of polydrug use.

Key Words: cognitive impairment • cannabis • ecstasy • MDMA

This version was published on July 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 5, 498-510 (2008)
DOI: 10.1177/0269881107081545


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement